menu
    • menu
    [{"orgOrder":0,"company":"Elizabeth Berry-Kravis","sponsor":"FRAXA Research Foundation | Purposeful IKE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotoxine Mesylate","moa":"Monoamine oxidase (MAO)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Elizabeth Berry-Kravis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elizabeth Berry-Kravis \/ FRAXA Research Foundation | Purposeful IKE","highestDevelopmentStatusID":"8","companyTruncated":"Elizabeth Berry-Kravis \/ FRAXA Research Foundation | Purposeful IKE"}]

    Find Clinical Drug Pipeline Developments & Deals for Hydrogenated Ergot Alkaloids

    Menu

    Hydrogenated Ergot Alkaloids

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elizabeth Berry-Kravis

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Elizabeth Berry-Kravis

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotoxine Mesylate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : FRAXA Research Foundation | Purposeful IKE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ERG/5-HTP in Fragile X Syndrome (FXS)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 01, 2021

                            Lead Product(s) : Dihydroergotoxine Mesylate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : FRAXA Research Foundation | Purposeful IKE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth